This is an RSS newsfeed from BioMed Central It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit http://www.biomedcentral.com/info/about/rss/ http://thomsoncurrentdrugs.com/products/journals/comtmostviewed/ Most viewed articles in last 30 days from Current Opinion in Molecular Therapeutics (ISSN 1464-8431) published by Current Drugs Limited. http://www.biomedcentral.com/1464-8431/10/158 T Nguyen, EM Menocal, J Harborth and JH Fruehauf Current Opinion in Molecular Therapeutics 2008, 10:158-167 Number of accesses: 37 2008-03-31 doi:10.1186/cd-891052 Current Opinion in Molecular Therapeutics 1464-8431 10 158 2008-03-31 Bristol-Myers Squibb is developing belatacept, a soluble fusion protein of the B7-binding domain of CTLA4 with amino acid changes A29Y and L104E and an Ig tail, which inhibits lymphocyte co-stimulation through CD28, for the potential treatment of solid organ transplant rejection. Belatacept is currently undergoing phase III clinical trials. http://www.biomedcentral.com/1464-8431/7/384 B Vanhove and J-P Soulillou Current Opinion in Molecular Therapeutics 2005, 7:384-393 Number of accesses: 25 2005-07-25 doi:10.1186/cd-614040 Current Opinion in Molecular Therapeutics 1464-8431 7 384 2005-07-25 http://www.biomedcentral.com/1464-8431/10/323 S Chumsri and AM Burger Current Opinion in Molecular Therapeutics 2008, 10:323-333 Number of accesses: 22 2008-07-30 doi:10.1186/cd-929733 Current Opinion in Molecular Therapeutics 1464-8431 10 323 2008-07-30 http://www.biomedcentral.com/1464-8431/10/393 G Hutas Current Opinion in Molecular Therapeutics 2008, 10:393-406 Number of accesses: 20 2008-07-30 doi:10.1186/cd-929750 Current Opinion in Molecular Therapeutics 1464-8431 10 393 2008-07-30 http://www.biomedcentral.com/1464-8431/9/345 A Aigner Current Opinion in Molecular Therapeutics 2007, 9:345-352 Number of accesses: 19 2007-08-08 doi:10.1186/cd-820444 Current Opinion in Molecular Therapeutics 1464-8431 9 345 2007-08-08 http://www.biomedcentral.com/1464-8431/10/150 J Mattes, A Collison and PS Foster Current Opinion in Molecular Therapeutics 2008, 10:150-157 Number of accesses: 18 2008-03-31 doi:10.1186/cd-891050 Current Opinion in Molecular Therapeutics 1464-8431 10 150 2008-03-31 Gemtuzumab ozogamicin (CMA-676) is a cytotoxic drug (calichaemicin) linked to a human monoclonal antibody that targets CD33, and which has been jointly developed and launched by Celltech Group and the Wyeth-Ayerst Research division of American Home Products as a treatment for acute myeloid leukemia (AML). http://www.biomedcentral.com/1464-8431/2/691 Duvaz I Niculescu Current Opinion in Molecular Therapeutics 2000, 2:691-696 Number of accesses: 14 2003-01-15 doi:10.1186/cd-476294 Current Opinion in Molecular Therapeutics 1464-8431 2 691 2003-01-15 Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection. http://www.biomedcentral.com/1464-8431/7/588 MA Morse Current Opinion in Molecular Therapeutics 2005, 7:588-597 Number of accesses: 13 2005-11-24 doi:10.1186/cd-636977 Current Opinion in Molecular Therapeutics 1464-8431 7 588 2005-11-24 http://www.biomedcentral.com/1464-8431/9/248 P Svoboda Current Opinion in Molecular Therapeutics 2007, 9:248-257 Number of accesses: 12 2007-06-07 doi:10.1186/cd-802937 Current Opinion in Molecular Therapeutics 1464-8431 9 248 2007-06-07 http://www.biomedcentral.com/1464-8431/10/168 M Faria and H Ulrich Current Opinion in Molecular Therapeutics 2008, 10:168-175 Number of accesses: 12 2008-03-31 doi:10.1186/cd-891054 Current Opinion in Molecular Therapeutics 1464-8431 10 168 2008-03-31